DMD054031 1975..1993

Prediction of human pharmacokinetics of new drugs, as well as other disposition attributes, has become a routine practice in drug research and development. Prior to the 1990s, drug disposition science was used in a mostly descriptive manner in the drug development phase. With the advent of in vitro methods and availability of human-derived reagents for in vitro studies, drug-disposition scientists became engaged in the compound design phase of drug discovery to optimize and predict human disposition properties prior to nomination of candidate compounds into the drug development phase. This has reaped benefits in that the attrition rate of new drug candidates in drug development for reasons of unacceptable pharmacokinetics has greatly decreased. Attributes that are predicted include clearance, volume of distribution, half-life, absorption, and drug-drug interactions. In this article, we offer our experience-based perspectives on the tools and methods of predicting human drug disposition using in vitro and animal data.

[1]  Sarfaraz K. Niazi Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System , 2004, Handbook of Pharmaceutical Manufacturing Formulations, Third Edition.

[2]  Karen Rowland-Yeo,et al.  Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans , 2013, Xenobiotica; the fate of foreign compounds in biological systems.

[3]  S. Haddad,et al.  Toward a new paradigm for the efficient in vitro-in vivo extrapolation of metabolic clearance in humans from hepatocyte data. , 2013, Journal of pharmaceutical sciences.

[4]  Karen Rowland-Yeo,et al.  Differences in Cytochrome P450-Mediated Pharmacokinetics Between Chinese and Caucasian Populations Predicted by Mechanistic Physiologically Based Pharmacokinetic Modelling , 2013, Clinical Pharmacokinetics.

[5]  H. Ellens,et al.  Optimizing the in vitro and clinical assessment of drug interaction risk by understanding co-medications in patient populations , 2013, Expert opinion on drug metabolism & toxicology.

[6]  Jian Lin,et al.  Quantitative Prediction of Repaglinide-Rifampicin Complex Drug Interactions Using Dynamic and Static Mechanistic Models: Delineating Differential CYP3A4 Induction and OATP1B1 Inhibition Potential of Rifampicin , 2013, Drug Metabolism and Disposition.

[7]  Hugh A Barton,et al.  Model-based approaches to predict drug–drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond , 2013, Expert opinion on drug metabolism & toxicology.

[8]  B. Feng,et al.  Response to the Comment on the Article “Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions” , 2013, Pharmaceutical Research.

[9]  A. D. Rodrigues,et al.  Cynomolgus Monkey as a Potential Model to Assess Drug Interactions Involving Hepatic Organic Anion Transporting Polypeptides: In Vitro, In Vivo, and In Vitro-to-In Vivo Extrapolation , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[10]  Franco Lombardo,et al.  Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 1: Volume of Distribution at Steady State , 2013, Journal of clinical pharmacology.

[11]  Franco Lombardo,et al.  Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 2: Clearance , 2013, Journal of clinical pharmacology.

[12]  Malcolm Rowland,et al.  Cyclosporine Inhibition of Hepatic and Intestinal CYP3A4, Uptake and Efflux Transporters: Application of PBPK Modeling in the Assessment of Drug-Drug Interaction Potential , 2012, Pharmaceutical Research.

[13]  S. Goutelle,et al.  In Vivo Quantitative Prediction of the Effect of Gene Polymorphisms and Drug Interactions on Drug Exposure for CYP2C19 Substrates , 2013, The AAPS Journal.

[14]  T. Goosen,et al.  Mechanistic Modeling to Predict the Transporter- and Enzyme-Mediated Drug-Drug Interactions of Repaglinide , 2013, Pharmaceutical Research.

[15]  Malcolm Rowland,et al.  Tissue lipids and drug distribution: dog versus rat. , 2012, Journal of pharmaceutical sciences.

[16]  R. Obach,et al.  Statistical Methods for Analysis of Time-Dependent Inhibition of Cytochrome P450 Enzymes , 2012, Drug Metabolism and Disposition.

[17]  K. Maeda,et al.  Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes. , 2012, Molecular pharmaceutics.

[18]  C. Hilgendorf,et al.  Understanding the Critical Disposition Pathways of Statins to Assess Drug–Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1 , 2012, Clinical pharmacology and therapeutics.

[19]  Christopher E. Keefer,et al.  Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design. , 2012, European journal of medicinal chemistry.

[20]  Aleksandra Galetin,et al.  Use of Mechanistic Modeling to Assess Interindividual Variability and Interspecies Differences in Active Uptake in Human and Rat Hepatocytes , 2012, Drug Metabolism and Disposition.

[21]  Li Di,et al.  A Novel Relay Method for Determining Low-Clearance Values , 2012, Drug Metabolism and Disposition.

[22]  D. Surry,et al.  Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[23]  T. Akabane,et al.  A quantitative approach to hepatic clearance prediction of metabolism by aldehyde oxidase using custom pooled hepatocytes , 2012, Xenobiotica; the fate of foreign compounds in biological systems.

[24]  B. Feng,et al.  Physicochemical Property Space of Hepatobiliary Transport and Computational Models for Predicting Rat Biliary Excretion , 2012, Drug Metabolism and Disposition.

[25]  J. Houston,et al.  Utility of Drug Depletion-Time Profiles in Isolated Hepatocytes for Accessing Hepatic Uptake Clearance: Identifying Rate-Limiting Steps and Role of Passive Processes , 2012, Drug Metabolism and Disposition.

[26]  The Development, Characterization, and Application of an OATP1B1 Inhibition Assay in Drug Discovery , 2012, Drug Metabolism and Disposition.

[27]  A. Rostami-Hodjegan,et al.  Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology , 2012, Clinical pharmacology and therapeutics.

[28]  M Rowland,et al.  Best Practice in the Use of Physiologically Based Pharmacokinetic Modeling and Simulation to Address Clinical Pharmacology Regulatory Questions , 2012, Clinical pharmacology and therapeutics.

[29]  Lawrence X. Yu,et al.  Prediction of volume of distribution at steady state in humans: comparison of different approaches , 2012, Expert opinion on drug metabolism & toxicology.

[30]  K. Maeda,et al.  Transporter‐Mediated Drug–Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies , 2012, Clinical pharmacology and therapeutics.

[31]  H. Barton,et al.  In Vitro Evaluation of Hepatic Transporter-Mediated Clinical Drug-Drug Interactions: Hepatocyte Model Optimization and Retrospective Investigation , 2012, Drug Metabolism and Disposition.

[32]  B. Feng,et al.  Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions , 2012, Pharmaceutical Research.

[33]  L. Tremaine,et al.  Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability – considerations for drug development , 2012, Expert opinion on drug metabolism & toxicology.

[34]  Hugh A. Barton,et al.  Mechanistic Pharmacokinetic Modeling for the Prediction of Transporter-Mediated Disposition in Humans from Sandwich Culture Human Hepatocyte Data , 2012, Drug Metabolism and Disposition.

[35]  L. Berezhkovskiy On the accuracy of determination of unbound drug fraction in tissue using diluted tissue homogenate. , 2012, Journal of pharmaceutical sciences.

[36]  I. Tamai Oral drug delivery utilizing intestinal OATP transporters. , 2012, Advanced drug delivery reviews.

[37]  Li Di,et al.  pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery. , 2012, Molecular pharmaceutics.

[38]  Yuan Chen,et al.  Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies , 2012, Biopharmaceutics & drug disposition.

[39]  M Rowland,et al.  The Role of Physiologically Based Pharmacokinetic Modeling in Regulatory Review , 2012, Clinical pharmacology and therapeutics.

[40]  Jan Snoeys,et al.  From preclinical to human – prediction of oral absorption and drug–drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example , 2012, Biopharmaceutics & drug disposition.

[41]  Yongling Xiao,et al.  Differential Modulation of Cytochrome P450 Activity and the Effect of 1-Aminobenzotriazole on Hepatic Transport in Sandwich-Cultured Human Hepatocytes , 2012, Drug Metabolism and Disposition.

[42]  Takashi Baba,et al.  Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry. , 2012, Analytical chemistry.

[43]  Dennis A. Smith Pfizer Sandwich Laboratories: where drug metabolism first met drug discovery , 2012, Xenobiotica; the fate of foreign compounds in biological systems.

[44]  Tetsuya Terasaki,et al.  Simultaneous Absolute Protein Quantification of Transporters, Cytochromes P450, and UDP-Glucuronosyltransferases as a Novel Approach for the Characterization of Individual Human Liver: Comparison with mRNA Levels and Activities , 2012, Drug Metabolism and Disposition.

[45]  K. Saleh,et al.  Comprehensive assessment. , 2012, Nursing older people.

[46]  France Mentré,et al.  Optimal Sampling Times for a Drug and its Metabolite using SIMCYP® Simulations as Prior Information , 2012, Clinical Pharmacokinetics.

[47]  G. Camenisch,et al.  Novel In Vitro-In Vivo Extrapolation (IVIVE) Method to Predict Hepatic Organ Clearance in Rat , 2011, Pharmaceutical Research.

[48]  L. Berry,et al.  Species Differences in Distribution and Prediction of Human Vss from Preclinical Data , 2011, Drug Metabolism and Disposition.

[49]  Li Di,et al.  Development of a new permeability assay using low-efflux MDCKII cells. , 2011, Journal of pharmaceutical sciences.

[50]  Y Kumagai,et al.  Identification of the Rate‐Determining Process in the Hepatic Clearance of Atorvastatin in a Clinical Cassette Microdosing Study , 2011, Clinical pharmacology and therapeutics.

[51]  Malcolm Rowland,et al.  PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution. , 2011, Journal of pharmaceutical sciences.

[52]  Aleksandra Galetin,et al.  Kinetic Characterization of Rat Hepatic Uptake of 16 Actively Transported Drugs , 2011, Drug Metabolism and Disposition.

[53]  K. Maeda,et al.  Culture Period-Dependent Changes in the Uptake of Transporter Substrates in Sandwich-Cultured Rat and Human Hepatocytes , 2011, Drug Metabolism and Disposition.

[54]  D. B. Duignan,et al.  pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. , 2011, Molecular pharmaceutics.

[55]  M. Jamei,et al.  Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[56]  Robert J Riley,et al.  Prediction of Human Renal Clearance from Preclinical Species for a Diverse Set of Drugs That Exhibit Both Active Secretion and Net Reabsorption , 2011, Drug Metabolism and Disposition.

[57]  Hannah M Jones,et al.  Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic Modelling , 2011, Clinical pharmacokinetics.

[58]  Aleksandra Galetin,et al.  Prediction of Human Drug Clearance by Multiple Metabolic Pathways: Integration of Hepatic and Intestinal Microsomal and Cytosolic Data , 2011, Drug Metabolism and Disposition.

[59]  Yuan Chen,et al.  Utility of Intersystem Extrapolation Factors in Early Reaction Phenotyping and the Quantitative Extrapolation of Human Liver Microsomal Intrinsic Clearance Using Recombinant Cytochromes P450 , 2011, Drug Metabolism and Disposition.

[60]  A. Hill,et al.  Estimating unbound volume of distribution and tissue binding by in vitro HPLC-based human serum albumin and immobilised artificial membrane-binding measurements. , 2011, Journal of pharmaceutical sciences.

[61]  G. S. Walker,et al.  Validation of Isolated Metabolites from Drug Metabolism Studies as Analytical Standards by Quantitative NMR , 2011, Drug Metabolism and Disposition.

[62]  P. Neuvonen,et al.  Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake , 2011, Pharmacological Reviews.

[63]  L Zhang,et al.  Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review , 2011, Clinical pharmacology and therapeutics.

[64]  Ruili Huang,et al.  Identification of Clinically Used Drugs That Activate Pregnane X Receptors , 2011, Drug Metabolism and Disposition.

[65]  D. B. Duignan,et al.  Characterization of Digoxin Uptake in Sandwich-Cultured Human Hepatocytes , 2011, Drug Metabolism and Disposition.

[66]  Amin Rostami-Hodjegan,et al.  Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models. , 2009, British journal of clinical pharmacology.

[67]  Yuichi Sugiyama,et al.  Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans , 2010, Journal of Pharmacokinetics and Pharmacodynamics.

[68]  Haiyan Li,et al.  Contribution of molecular properties to extrapolation of the volume of distribution in human from preclinical animal species data , 2010, Biopharmaceutics & drug disposition.

[69]  Y. Mizuki,et al.  Prediction of the Intestinal First-Pass Metabolism of CYP3A Substrates in Humans Using Cynomolgus Monkeys , 2010, Drug Metabolism and Disposition.

[70]  Sean Ekins,et al.  Using Open Source Computational Tools for Predicting Human Metabolic Stability and Additional Absorption, Distribution, Metabolism, Excretion, and Toxicity Properties , 2010, Drug Metabolism and Disposition.

[71]  Jianghong Fan,et al.  PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism. , 2010, Current drug metabolism.

[72]  Y. Sugiyama,et al.  Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein. , 2010, Current drug metabolism.

[73]  A Rostami-Hodjegan,et al.  Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. , 2010, Current drug metabolism.

[74]  Sharon L Ripp,et al.  Evaluation of models for predicting drug–drug interactions due to induction , 2010, Expert opinion on drug metabolism & toxicology.

[75]  Hiroshi Yamazaki,et al.  Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution. , 2010, Current drug metabolism.

[76]  R. Obach,et al.  Cytochrome P450 3A4 mRNA Is a More Reliable Marker than CYP3A4 Activity for Detecting Pregnane X Receptor-Activated Induction of Drug-Metabolizing Enzymes , 2010, Drug Metabolism and Disposition.

[77]  Kuresh Youdim,et al.  In Vitro-In Vivo Correlation for Intrinsic Clearance for Drugs Metabolized by Human Aldehyde Oxidase , 2010, Drug Metabolism and Disposition.

[78]  J. Houston,et al.  Prediction of Human Metabolic Clearance from In Vitro Systems: Retrospective Analysis and Prospective View , 2010, Pharmaceutical Research.

[79]  F. Lombardo,et al.  Use of the Øie-Tozer Model in Understanding Mechanisms and Determinants of Drug Distribution , 2010, Drug Metabolism and Disposition.

[80]  Michael Gertz,et al.  Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data , 2010, Drug Metabolism and Disposition.

[81]  Ying-Hong Wang,et al.  Confidence Assessment of the Simcyp Time-Based Approach and a Static Mathematical Model in Predicting Clinical Drug-Drug Interactions for Mechanism-Based CYP3A Inhibitors , 2010, Drug Metabolism and Disposition.

[82]  D. B. Duignan,et al.  Understanding the clinical pharmacokinetics of a GABAA partial agonist by application of in vitro tools , 2010, Xenobiotica; the fate of foreign compounds in biological systems.

[83]  Y. Lai,et al.  Improved extrapolation of hepatobiliary clearance from in vitro sandwich cultured rat hepatocytes through absolute quantification of hepatobiliary transporters. , 2010, Molecular pharmaceutics.

[84]  Masoud Jamei,et al.  Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[85]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[86]  R Scott Obach,et al.  Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. , 2010, Journal of medicinal chemistry.

[87]  V. Kumar,et al.  Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data , 2008, European Journal of Drug Metabolism and Pharmacokinetics.

[88]  Gary W. Caldwell,et al.  Allometric scaling of pharmacokinetic parameters in drug discovery: Can human CL, Vss and t1/2 be predicted fromin-vivo rat data? , 2004, European Journal of Drug Metabolism and Pharmacokinetics.

[89]  A. Guillouzo,et al.  General review on in vitro hepatocyte models and their applications. , 2010, Methods in molecular biology.

[90]  Guideline on the Investigation of Drug Interactions , 2010 .

[91]  J. Beijnen,et al.  Inhibition and Stimulation of Intestinal and Hepatic CYP3A Activity: Studies in Humanized CYP3A4 Transgenic Mice Using Triazolam , 2009, Drug Metabolism and Disposition.

[92]  S. Yamashita,et al.  The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans. , 2009, Journal of pharmaceutical sciences.

[93]  Y. Lai,et al.  Identification of interspecies difference in hepatobiliary transporters to improve extrapolation of human biliary secretion , 2009, Expert opinion on drug metabolism & toxicology.

[94]  Alex Phipps,et al.  Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction , 2009, Drug Metabolism and Disposition.

[95]  Marilyn E. Morris,et al.  Prediction of Biliary Excretion in Rats and Humans Using Molecular Weight and Quantitative Structure–Pharmacokinetic Relationships , 2009, The AAPS Journal.

[96]  Kazuya Maeda,et al.  Prediction of the Hepatic and Renal Clearance of Transporter Substrates in Rats Using in Vitro Uptake Experiments , 2009, Drug Metabolism and Disposition.

[97]  Vikram Sinha,et al.  In Vitro and in Vivo Induction of Cytochrome P450: A Survey of the Current Practices and Recommendations: A Pharmaceutical Research and Manufacturers of America Perspective , 2009, Drug Metabolism and Disposition.

[98]  Leslie Z. Benet,et al.  The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs , 2009, Pharmaceutical Research.

[99]  Franco Lombardo,et al.  In silico prediction of volume of distribution in human using linear and nonlinear models on a 669 compound data set. , 2009, Journal of medicinal chemistry.

[100]  Peter J H Webborn,et al.  Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry. , 2009, Molecular pharmaceutics.

[101]  Bill J Smith,et al.  Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches , 2009, Journal of clinical pharmacology.

[102]  M Jamei,et al.  Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. , 2009, Current drug metabolism.

[103]  Claire Strain-Damerell,et al.  Evaluation of Recombinant Cytochrome P450 Enzymes as an in Vitro System for Metabolic Clearance Predictions , 2009, Drug Metabolism and Disposition.

[104]  Yuichi Sugiyama,et al.  Prediction of Hepatic Clearance in Human From In Vitro Data for Successful Drug Development , 2009, The AAPS Journal.

[105]  Leslie Z. Benet,et al.  Effects of Drug Transporters on Volume of Distribution , 2009, The AAPS Journal.

[106]  Sebastian Polak,et al.  Population-Based Mechanistic Prediction of Oral Drug Absorption , 2009, The AAPS Journal.

[107]  B. Långström,et al.  Species Differences in Blood-Brain Barrier Transport of Three Positron Emission Tomography Radioligands with Emphasis on P-Glycoprotein Transport , 2009, Drug Metabolism and Disposition.

[108]  Kairui Feng,et al.  The Simcyp® Population-based ADME Simulator , 2009 .

[109]  Caroline A. Lee,et al.  Drug–Drug Interactions Mediated Through P‐Glycoprotein: Clinical Relevance and In Vitro–In Vivo Correlation Using Digoxin as a Probe Drug , 2009, Clinical pharmacology and therapeutics.

[110]  Kazuya Maeda,et al.  Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans , 2009, Journal of Pharmacology and Experimental Therapeutics.

[111]  Aleksandra Galetin,et al.  Prediction of Drug Clearance by Glucuronidation from in Vitro Data: Use of Combined Cytochrome P450 and UDP-Glucuronosyltransferase Cofactors in Alamethicin-Activated Human Liver Microsomes , 2009, Drug Metabolism and Disposition.

[112]  Kairui Feng,et al.  The Simcyp population-based ADME simulator. , 2009, Expert opinion on drug metabolism & toxicology.

[113]  Dennis A Smith,et al.  Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research? , 2009, Current opinion in drug discovery & development.

[114]  R. Obach Predicting drug-drug interactions from in vitro drug metabolism data: challenges and recent advances. , 2009, Current opinion in drug discovery & development.

[115]  Yuichi Sugiyama,et al.  In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. , 2009, Drug metabolism and pharmacokinetics.

[116]  M. Niemi,et al.  Effects of Gemfibrozil and Atorvastatin on the Pharmacokinetics of Repaglinide in Relation to SLCO1B1 Polymorphism , 2008, Clinical pharmacology and therapeutics.

[117]  Meng Li,et al.  Identification of interspecies difference in efflux transporters of hepatocytes from dog, rat, monkey and human. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[118]  K. Brouwer,et al.  In Vitro Biliary Clearance of Angiotensin II Receptor Blockers and 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase Inhibitors in Sandwich-Cultured Rat Hepatocytes: Comparison with in Vivo Biliary Clearance , 2008, Journal of Pharmacology and Experimental Therapeutics.

[119]  J. Sahi,et al.  Current Industrial Practices in Assessing CYP450 Enzyme Induction: Preclinical and Clinical , 2008, The AAPS Journal.

[120]  Tristan S. Maurer,et al.  A Combined Model for Predicting CYP3A4 Clinical Net Drug-Drug Interaction Based on CYP3A4 Inhibition, Inactivation, and Induction Determined in Vitro , 2008, Drug Metabolism and Disposition.

[121]  Rikiya Ohashi,et al.  Effect of Plasma Protein Binding on in Vitro-in Vivo Correlation of Biliary Excretion of Drugs Evaluated by Sandwich-Cultured Rat Hepatocytes , 2008, Drug Metabolism and Disposition.

[122]  J. Houston,et al.  Rate-Limiting Steps in Hepatic Drug Clearance: Comparison of Hepatocellular Uptake and Metabolism with Microsomal Metabolism of Saquinavir, Nelfinavir, and Ritonavir , 2008, Drug Metabolism and Disposition.

[123]  W. Heizer,et al.  A novel method for the determination of biliary clearance in humans , 2004, The AAPS Journal.

[124]  K. Thummel Gut instincts: CYP3A4 and intestinal drug metabolism. , 2007, The Journal of clinical investigation.

[125]  H. Einolf Comparison of different approaches to predict metabolic drug–drug interactions , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[126]  R J Riley,et al.  In vitro–in vivo extrapolation of hepatic clearance involving active uptake: Theoretical and experimental aspects , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[127]  Masoud Jamei,et al.  Prediction of intestinal first-pass drug metabolism. , 2007, Current drug metabolism.

[128]  Manfred Kansy,et al.  High throughput solubility measurement in drug discovery and development. , 2007, Advanced drug delivery reviews.

[129]  Jochem Alsenz,et al.  Development of a partially automated solubility screening (PASS) assay for early drug development. , 2007, Journal of pharmaceutical sciences.

[130]  M. Jamei,et al.  Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[131]  Ken Grime,et al.  Use of Hepatocytes to Assess the Contribution of Hepatic Uptake to Clearance in Vivo , 2007, Drug Metabolism and Disposition.

[132]  W. Heizer,et al.  In Vitro–In Vivo Correlation of Hepatobiliary Drug Clearance in Humans , 2007, Clinical pharmacology and therapeutics.

[133]  L J Lesko,et al.  Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling , 2007, Clinical pharmacology and therapeutics.

[134]  R. Obach Chapter 30 Prediction of Human Volume of Distribution Using in vivo, in vitro, and in silico Approaches , 2007 .

[135]  A. D. Rodrigues,et al.  Pharmacokinetic Drug Interactions Involving 17α-Ethinylestradiol , 2007 .

[136]  John C Lipscomb,et al.  Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. , 2007, Current drug metabolism.

[137]  A. D. Rodrigues,et al.  Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. , 2007, Clinical pharmacokinetics.

[138]  Malcolm Rowland,et al.  Mechanistic Approaches to Volume of Distribution Predictions: Understanding the Processes , 2007, Pharmaceutical Research.

[139]  Hans Lennernäs,et al.  Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[140]  Anne Hersey,et al.  Estimation of volume of distribution in humans from high throughput HPLC-based measurements of human serum albumin binding and immobilized artificial membrane partitioning. , 2006, Journal of medicinal chemistry.

[141]  Yuichi Sugiyama,et al.  Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. , 2006, Pharmacology & therapeutics.

[142]  Diana Kazolias,et al.  Use of Cryopreserved Human Hepatocytes in Sandwich Culture to Measure Hepatobiliary Transport , 2006, Drug Metabolism and Disposition.

[143]  Michael Mayersohn,et al.  A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry. , 2006, Journal of pharmaceutical sciences.

[144]  Ho-Chul Shin,et al.  Why is it Challenging to Predict Intestinal Drug Absorption and Oral Bioavailability in Human Using Rat Model , 2006, Pharmaceutical Research.

[145]  K Rowland-Yeo,et al.  Prediction of in vivo drug clearance from in vitro data. II: Potential inter-ethnic differences , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[146]  M. Rowland,et al.  Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. , 2006, Journal of pharmaceutical sciences.

[147]  Mary F Paine,et al.  THE HUMAN INTESTINAL CYTOCHROME P450 “PIE” , 2006, Drug Metabolism and Disposition.

[148]  Yuichi Sugiyama,et al.  Transporters as a determinant of drug clearance and tissue distribution. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[149]  Franco Lombardo,et al.  A hybrid mixture discriminant analysis-random forest computational model for the prediction of volume of distribution of drugs in human. , 2006, Journal of medicinal chemistry.

[150]  H. Kusuhara,et al.  Is the Monkey an Appropriate Animal Model to Examine Drug-Drug Interactions Involving Renal Clearance? Effect of Probenecid on the Renal Elimination of H2 Receptor Antagonists , 2006, Journal of Pharmacology and Experimental Therapeutics.

[151]  M Paul Gleeson,et al.  In silico human and rat Vss quantitative structure-activity relationship models. , 2006, Journal of medicinal chemistry.

[152]  J. Houston,et al.  The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions , 2006, Journal of Pharmacology and Experimental Therapeutics.

[153]  M. Jamei,et al.  Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[154]  Alex Avdeef,et al.  The rise of PAMPA , 2005, Expert opinion on drug metabolism & toxicology.

[155]  M. Varma,et al.  Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability. , 2005, Journal of pharmaceutical sciences.

[156]  Kiyomi Ito,et al.  IMPACT OF PARALLEL PATHWAYS OF DRUG ELIMINATION AND MULTIPLE CYTOCHROME P450 INVOLVEMENT ON DRUG-DRUG INTERACTIONS: CYP2D6 PARADIGM , 2005, Drug Metabolism and Disposition.

[157]  Mikko Niemi,et al.  Polymorphic Organic Anion Transporting Polypeptide 1B1 is a Major Determinant of Repaglinide Pharmacokinetics , 2005, Clinical pharmacology and therapeutics.

[158]  M. Rowland,et al.  Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. , 2005, Journal of pharmaceutical sciences.

[159]  H. Kusuhara,et al.  Molecular Cloning and Functional Analyses of OAT1 and OAT3 from Cynomolgus Monkey Kidney , 2005, Pharmaceutical Research.

[160]  Tony K L Kiang,et al.  UDP-glucuronosyltransferases and clinical drug-drug interactions. , 2005, Pharmacology & therapeutics.

[161]  Per Artursson,et al.  Caco-2 permeability of weakly basic drugs predicted with the Double-Sink PAMPA method , 2005 .

[162]  K. Pang,et al.  THE ROLES OF TRANSPORTERS AND ENZYMES IN HEPATIC DRUG PROCESSING , 2005, Drug Metabolism and Disposition.

[163]  Harold Boxenbaum,et al.  Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics , 1982, Journal of Pharmacokinetics and Biopharmaceutics.

[164]  Malcolm Rowland,et al.  Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance , 1977, Journal of Pharmacokinetics and Biopharmaceutics.

[165]  Malcolm Rowland,et al.  Kinetics of drug-drug interactions , 1973, Journal of Pharmacokinetics and Biopharmaceutics.

[166]  Robert L. Dedrick,et al.  Animal scale-up , 1973, Journal of Pharmacokinetics and Biopharmaceutics.

[167]  Malcolm Rowland,et al.  Clearance concepts in pharmacokinetics , 1973, Journal of Pharmacokinetics and Biopharmaceutics.

[168]  P. Artursson,et al.  Caco-2 permeability of weakly basic drugs predicted with the double-sink PAMPA pKa(flux) method. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[169]  Barry C. Jones,et al.  DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS , 2004, Drug Metabolism and Disposition.

[170]  L. Benet,et al.  Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[171]  Vinod Nair,et al.  Biopharmaceutic classification system: a scientific framework for pharmacokinetic optimization in drug research. , 2004, Current drug metabolism.

[172]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[173]  Yoshitaka Yano,et al.  Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles. , 2004, Journal of pharmaceutical sciences.

[174]  L. Berezhkovskiy,et al.  Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. , 2004, Journal of pharmaceutical sciences.

[175]  Keith W Ward,et al.  A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[176]  Keith W Ward,et al.  A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[177]  Kim L. R. Brouwer,et al.  The Complexities of Hepatic Drug Transport: Current Knowledge and Emerging Concepts , 2004, Pharmaceutical Research.

[178]  M. Cronin,et al.  Quantitative structure‐pharmacokinetic relationship modelling: apparent volume of distribution , 2004, The Journal of pharmacy and pharmacology.

[179]  Oliver Burk,et al.  Cytochrome P450 3A4 and P‐glycoprotein Expression in Human Small Intestinal Enterocytes and Hepatocytes: A Comparative Analysis in Paired Tissue Specimens , 2004, Clinical pharmacology and therapeutics.

[180]  G. Tucker,et al.  Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors , 2004, Xenobiotica; the fate of foreign compounds in biological systems.

[181]  M. Machida,et al.  Biopharmaceutics Classification by High Throughput Solubility Assay and PAMPA , 2004, Drug development and industrial pharmacy.

[182]  Vinod P. Shah,et al.  Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions , 2002, Pharmaceutical Research.

[183]  Paul W. Buehler,et al.  Comparison of Oral Absorption and Bioavailability of Drugs Between Monkey and Human , 2002, Pharmaceutical Research.

[184]  Hyunyoung Jeong,et al.  Evaluation of Using Dog as an Animal Model to Study the Fraction of Oral Dose Absorbed of 43 Drugs in Humans , 2000, Pharmaceutical Research.

[185]  A. Barve,et al.  Linear Correlation of the Fraction of Oral Dose Absorbed of 64 Drugs Between Humans and Rats , 1998, Pharmaceutical Research.

[186]  Hans Lennernäs,et al.  Comparison Between Permeability Coefficients in Rat and Human Jejunum , 1996, Pharmaceutical Research.

[187]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[188]  Leslie Z. Benet,et al.  Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.

[189]  Amy Roe,et al.  The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[190]  K. Pang,et al.  Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[191]  Scott L Cockroft,et al.  The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[192]  Amin Rostami-Hodjegan,et al.  The effects of portal shunts on intestinal cytochrome P450 3A activity , 2002, Hepatology.

[193]  Patrick Poulin,et al.  Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. , 2002, Journal of pharmaceutical sciences.

[194]  Michael Levin Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System , 2001 .

[195]  B Agoram,et al.  Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.

[196]  L. Benet,et al.  Active secretion and enterocytic drug metabolism barriers to drug absorption. , 2001, Advanced drug delivery reviews.

[197]  J. Legendre,et al.  Determination of the Aqueous Solubility of Drugs Using a Convenient 96-Well Plate-Based Assay , 2001, Drug development and industrial pharmacy.

[198]  F. Russel,et al.  Mechanisms and clinical implications of renal drug excretion* , 2001, Drug metabolism reviews.

[199]  J S Harmatz,et al.  Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[200]  R. Obach Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[201]  C. Bevan,et al.  A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. , 2000, Analytical chemistry.

[202]  K. Pang,et al.  A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[203]  R. Obach,et al.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[204]  G L Amidon,et al.  A compartmental absorption and transit model for estimating oral drug absorption. , 1999, International journal of pharmaceutics.

[205]  I. Mahmood Prediction of Clearance, Volume of Distribution and Half‐life by Allometric Scaling and by use of Plasma Concentrations Predicted from Pharmacokinetic Constants: a Comparative Study , 1999, The Journal of pharmacy and pharmacology.

[206]  X Liu,et al.  Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[207]  T Lavé,et al.  Prediction of Hepatic Metabolic Clearance Based on Interspecies Allometric Scaling Techniques and In Vitro-In Vivo Correlations , 1999, Clinical pharmacokinetics.

[208]  Y. Sugiyama,et al.  Transporters for bile acids and organic anions. , 1999, Pharmaceutical biotechnology.

[209]  J. Tolan,et al.  MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. , 1999, Journal of pharmaceutical sciences.

[210]  I Mahmood,et al.  Interspecies scaling of renally secreted drugs. , 1998, Life sciences.

[211]  R. Obach,et al.  Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[212]  D J Rance,et al.  The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.

[213]  D. Keppler,et al.  Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. , 1997, Biological chemistry.

[214]  M. Müller,et al.  Molecular aspects of hepatobiliary transport. , 1997, The American journal of physiology.

[215]  R C Chou,et al.  Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. , 1997, Journal of pharmaceutical sciences.

[216]  D. Keppler,et al.  Introduction: Transport across the hepatocyte canalicular membrane , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[217]  T Ishizaki,et al.  Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. , 1997, Pharmacology & therapeutics.

[218]  M. Yamazaki,et al.  Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinemic rats. , 1996, Biopharmaceutics & drug disposition.

[219]  D. Shen,et al.  First‐pass metabolism of midazolam by the human intestine , 1996, Clinical pharmacology and therapeutics.

[220]  T. Ishikawa,et al.  How does the MRP/GS-X pump export doxorubicin? , 1996, Journal of the National Cancer Institute.

[221]  J. Lin,et al.  Species similarities and differences in pharmacokinetics. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[222]  J B Houston,et al.  Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.

[223]  S. Jezequel Fluconazole: Interspecies Scaling and Allometric Relationships of Pharmacokinetic Properties , 1994, The Journal of pharmacy and pharmacology.

[224]  P. Artursson,et al.  Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. , 1991, Biochemical and biophysical research communications.

[225]  P. Artursson,et al.  Epithelial transport of drugs in cell culture. II: Effect of extracellular calcium concentration on the paracellular transport of drugs of different lipophilicities across monolayers of intestinal epithelial (Caco-2) cells. , 1990, Journal of pharmaceutical sciences.

[226]  P. Artursson,et al.  Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. , 1990, Journal of pharmaceutical sciences.

[227]  J. Mordenti,et al.  Man versus beast: pharmacokinetic scaling in mammals. , 1986, Journal of pharmaceutical sciences.

[228]  S. Bryson Clinical Pharmacokinetics: Concepts and applications. , 1983 .

[229]  S Oie,et al.  Effect of altered plasma protein binding on apparent volume of distribution. , 1979, Journal of pharmaceutical sciences.

[230]  G R Wilkinson,et al.  Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. , 1977, The Journal of pharmacology and experimental therapeutics.

[231]  Grant R. Wilkinson,et al.  A physiological approach to hepatic drug clearance , 1975 .

[232]  G R Wilkinson,et al.  Commentary: a physiological approach to hepatic drug clearance. , 1975, Clinical pharmacology and therapeutics.

[233]  J. Gillette FACTORS AFFECTING DRUG METABOLISM , 1971, Annals of the New York Academy of Sciences.

[234]  Guidance for Industry Drug Interaction Studies — Study Design , Data Analysis , Implications for Dosing , and Labeling Recommendations , 2022 .